-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The FDA approved the second oral drug for COVID-19 to respond to Omi Keron's challenge
After Pfizer's COVID-19 oral drug Paxlovid was granted emergency use rights, the FDA approved the development of similar drugs by Merck & Co.
The antiviral drug Molnupiravir, jointly developed by Merck and Ridgeback Biotherapy, effectively reduces the risk of hospitalization and death by approximately 30%
Compared with Molnupiravir, Pfizer’s experimental oral drug Paxlovid can reduce the risk of hospitalization or death in high-risk COVID-19 patients by up to 89%
Last month, the FDA advisory committee recommended the use of Molnupiravir as much as possible with a slight advantage
The FDA on Thursday advised patients to use contraceptives during the medication and continue contraception within 4 days after the last medication
The agency stated that the potential side effects of Molnupiravir include diarrhea, nausea and dizziness
In a report submitted to the FDA expert panel, scientists from Merck said that they expect the drug to be effective against the Omicron variant virus, which contains mutations similar to other strains, but further testing is still needed
Merck’s entire course of treatment includes 40 tablets, each with 200 mg, twice a day for 5 consecutive days
At an expert meeting in November, Merck & Co.
Health experts have always believed that the introduction of oral anti-coronavirus drugs will bring hope to the end of the epidemic, because it allows patients to receive treatment at home without the need for professional injections or droppers
If these drugs can be delivered in time, they will help reduce the pressure on the medical system during the anticipated Omicron epidemic
The US government has spent 5 billion yuan to purchase 10 million treatment courses of Paxlovid and has pledged to order approximately 3.